Is telomerase a viable target in cancer?

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 730, Issue 1-2, 2012, Pages 90-97

  Buseman, C M ^a   Wright, W E ^a   Shay, J W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Senescence; Telomeres; Virotherapy

Indexed keywords

CANCER VACCINE; CAPECITABINE; DNA; FREUND ADJUVANT; GEMCITABINE; GRN 163 L; GRNVAC 1; HOLOENZYME; IMETELSTAT; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PEPTIDE VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TELOMELYSIN; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE[540-548] PEPTIDE VACCINE; TEMOZOLOMIDE; TERTOMOTIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BRAIN TUMOR; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL AGING; CELL DIVISION; CELL SENESCENCE; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC LYMPHOPROLIFERATIVE DISEASE; CUTANEOUS T CELL LYMPHOMA; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PANCREAS CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SENESCENCE; SOLID TUMOR; SOMATIC CELL; SUICIDE GENE THERAPY; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS;

EID: 84855500815     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2011.07.006     Document Type: Review

References (139)

1. Shay J.W., Wright W.E. Telomerase: a target for cancer therapeutics. Cancer Cell 2002, 2:257-265.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:6622-6626.
4. Griffith J.D, Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., de Lange T. Mammalian telomeres end in a large duplex loop. Cell 1999, 97:503-514.
5. Greider C.W. Telomeres do D-loop-T-loop. Cell 1999, 97:419-422.
6. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19:2100-2110.
7. Palm W., de Lange T. How shelterin protects mammalian telomeres. Annu. Rev. Genet. 2008, 42:301-334.
8. Smogorzewska A., de Lange T. Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem. 2004, 73:177-208.
9. Harley C.B. Telomere loss: mitotic clock or genetic time bomb?. Mutat. Res. 1991, 256:271-282.
10. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 2002, 27:339-344.
11. Shore D., Bianchi A. Telomere length regulation: coupling DNA end processing to feedback regulation of telomerase. EMBO J. 2009, 28:2309-2322.
12. Takai H., Smogorzewska A., de Lange T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 2003, 13:1549-1556.
13. Silverman J., Takai H., Buonomo S.B., Eisenhaber F., de Lange T. Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint. Genes Dev. 2004, 18:2108-2119.
14. Herbig U., Jobling W.A., Chen B.P., Chen D.J., Sedivy J.M. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 2004, 14:501-513.
15. Denchi E.L., de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007, 448:1068-1071.
16. Fagagna F.d.A.d., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., von Zglinicki T., Saretzki G., Carter N.P., Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
17. Zou Y., Sfeir A., Gryaznov S.M., Shay J.W., Wright W.E. Does a sentinel or a subset of short telomeres determine replicative senescence?. Mol. Biol. Cell 2004, 15:3709-3718.
18. Karlseder J., Broccoli D., Dai Y., Hardy S., de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999, 283:1321-1325.
19. Shay J.W., Wright W.E. Telomerase activity in human cancer. Curr. Opin. Oncol. 1996, 8:66-71.
20. van Steensel B., Smogorzewska A., de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998, 92:401-413.
21. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.L., Gottlieb G.J., Greider C.W., DePinho R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97:527-538.
22. Shay J.W., Pereira-Smith O.M., Wright W.E. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res. 1991, 196:33-39.
23. Wright W.E., Shay J.W. The two-stage mechanism controlling cellular senescence and immortalization. Exp. Gerontol. 1992, 27:383-389.
24. Wright W.E., Pereira-Smith O.M., Shay J.W. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol. Cell. Biol. 1989, 9:3088-3092.
25. Macera-Bloch L., Houghton J., Lenahan M., Jha K.K., Ozer H.L. Termination of lifespan of SV40-transformed human fibroblasts in crisis is due to apoptosis. J. Cell. Physiol. 2002, 190:332-344.
26. Zhang X., Mar V., Zhou W., Harrington L., Robinson M.O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999, 13:2388-2399.
27. Shay J.W., Wright W.E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005, 26:867-874.
28. Shay J.W., Wright W.E., Brasiskyte D., Van der Haegen B.A. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 1993, 8:1407-1413.
29. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
30. Counter C.M., Avilion A.A., LeFeuvre C.E., Stewart N.G., Greider C.W., Harley C.B., Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992, 11:1921-1929.
31. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 1997, 33:787-791.
32. Reddel R.R. Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett. 2003, 194:155-162.
33. Wright W.E, Piatyszek M.A., Rainey W.E., Byrd W., Shay J.W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 1996, 18:173-179.
34. Collins K., Mitchell J.R. Telomerase in the human organism. Oncogene 2002, 21:564-579.
35. Harrington L., McPhail T., Mar V., Zhou W., Oulton R., Bass M.B., Arruda I., Robinson M.O. A mammalian telomerase-associated protein. Science 1997, 275:973-977.
36. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Lingner J., Harley C.B., Cech T.R. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959.
37. Feng J., Funk W.D., Wang S.S., Weinrich S.L., Avilion A.A., Chiu C.P., Adams R.R., Chang E., Allsopp R.C., Yu J., et al. The RNA component of human telomerase. Science 1995, 269:1236-1241.
38. Harrington L., Zhou W., McPhail T., Oulton R., Yeung D.S., Mar V., Bass M.B., Robinson M.O. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 1997, 11:3109-3115.
39. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S., Haber D.A., Weinberg R.A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785-795.
40. Ducrest A.L, Szutorisz H., Lingner J., Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002, 21:541-552.
41. Takakura M., Kyo S., Kanaya T., Tanaka M., Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 1998, 58:1558-1561.
42. Cong Y.S., Wright W.E., Shay J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 2002, 66:407-425. (table of contents).
43. Kelleher C., Teixeira M.T., Forstemann K., Lingner J. Telomerase: biochemical considerations for enzyme and substrate. Trends Biochem. Sci. 2002, 27:572-579.
44. Schnapp G., Rodi H.P., Rettig W.J., Schnapp A., Damm K. One-step affinity purification protocol for human telomerase. Nucleic Acids Res. 1998, 26:3311-3313.
45. Cohen S.B., Graham M.E., Lovrecz G.O., Bache N., Robinson P.J., Reddel R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315:1850-1853.
46. Cristofari G., Lingner J. Telomere length homeostasis requires that telomerase levels are limiting. EMBO J. 2006, 25:565-574.
47. De Boeck G., Forsyth R.G., Praet M., Hogendoorn P.C. Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J. Pathol. 2009, 217:327-344.
48. Forsyth N.R., Wright W.E., Shay J.W. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation 2002, 69:188-197.
49. Herbert B.S, Hochreiter A.E., Wright W.E., Shay J.W. Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol. Nat. Protoc. 2006, 1:1583-1590.
50. Wright W.E., Shay J.W., Piatyszek M.A. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 1995, 23:3794-3795.
51. Hess J.L, Highsmith W.E. Telomerase detection in body fluids. Clin. Chem. 2002, 48:18-24.
52. Bryan T.M., Englezou A., Dalla-Pozza L., Dunham M.A., Reddel R.R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 1997, 3:1271-1274.
53. Henson J.D., Neumann A.A., Yeager T.R., Reddel R.R. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002, 21:598-610.
54. Hiyama E., Hiyama K., Yokoyama T., Matsuura Y., Piatyszek M.A., Shay J.W. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med. 1995, 1:249-255.
55. Ouellette M.M., Choi K.H. Telomeres and telomerase in ageing and cancer. Encyclopedia of Life Sciences 2007, John Wiley & Sons Ltd., Chichester, UK, (http://www.els.net/).
56. Dikmen Z.G., Wright W.E., Shay J.W., Gryaznov S.M. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells. J. Cell. Biochem. 2008, 104:444-452.
57. Shay J.W., Wright W.E. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 2005, 7:1-2.
58. White L.K., Wright W.E., Shay J.W. Telomerase inhibitors. Trends Biotechnol. 2001, 19:114-120.
59. Hamilton S.E., Pitts A.E., Katipally R.R., Jia X., Rutter J.P., Davies B.A., Shay J.W., Wright W.E., Corey D.R. Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry 1997, 36:11873-11880.
60. Norton J.C., Piatyszek M.A., Wright W.E., Shay J.W., Corey D.R. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 1996, 14:615-619.
61. Dikmen Z.G., Gellert G.C., Jackson S., Gryaznov S., Tressler R., Dogan P., Wright W.E., Shay J.W. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 2005, 65:7866-7873.
62. Gryaznov S.M., Jackson S., Dikmen G., Harley C., Herbert B.S., Wright W.E., Shay J.W. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Nucleosides Nucleotides Nucleic Acids 2007, 26:1577-1579.
63. Jackson S.R., Zhu C.H., Paulson V., Watkins L., Dikmen Z.G., Gryaznov S.M., Wright W.E., Shay J.W. Antiadhesive effects of GRN163L-an oligonucleotide N3'→P5' thio-phosphoramidate targeting telomerase. Cancer Res. 2007, 67:1121-1129.
64. Gellert G.C., Dikmen Z.G., Wright W.E., Gryaznov S., Shay J.W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 2006, 96:73-81.
65. Herbert B.S, Gellert G.C., Hochreiter A., Pongracz K., Wright W.E., Zielinska D., Chin A.C., Harley C.B., Shay J.W., Gryaznov S.M. Lipid modification of GRN163, an N3'→P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005, 24:5262-5268.
66. Hochreiter A.E., Xiao H., Goldblatt E.M., Gryaznov S.M., Miller K.D., Badve S., Sledge G.W., Herbert B.S. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin. Cancer Res. 2006, 12:3184-3192.
67. Gomez-Millan J., Goldblatt E.M., Gryaznov S.M., Mendonca M.S., Herbert B.S. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67:897-905.
68. Djojosubroto M.W., Chin A.C., Go N., Schaetzlein S., Manns M.P., Gryaznov S., Harley C.B., Rudolph K.L. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005, 42:1127-1136.
69. Ozawa T., Gryaznov S.M., Hu L.J., Pongracz K., Santos R.A., Bollen A.W., Lamborn K.R., Deen D.F. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-oncol 2004, 6:218-226.
70. Wang E.S., Wu K., Chin A.C., Chen-Kiang S., Pongracz K., Gryaznov S., Moore M.A. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004, 103:258-266.
71. Akiyama M., Hideshima T., Shammas M.A., Hayashi T., Hamasaki M., Tai Y.T., Richardson P., Gryaznov S., Munshi N.C., Anderson K.C. Effects of oligonucleotide N3'→P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003, 63:6187-6194.
72. Herbert B.S., Pongracz K., Shay J.W., Gryaznov S.M., Shea-Herbert B. Oligonucleotide N3'→P5' phosphoramidates as efficient telomerase inhibitors. Oncogene 2002, 21:638-642.
73. Asai A., Oshima Y., Yamamoto Y., Uochi T.A., Kusaka H., Akinaga S., Yamashita Y., Pongracz K., Pruzan R., Wunder E., Piatyszek M., Li S., Chin A.C., Harley C.B., Gryaznov S. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003, 63:3931-3939.
74. Gryaznov S., Pongracz K., Matray T., Schultz R., Pruzan R., Aimi J., Chin A., Harley C., Shea-Herbert B., Shay J., Oshima Y., Asai A., Yamashita Y. Telomerase inhibitors-oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids 2001, 20:401-410.
75. Shammas M.A., Qazi A., Batchu R.B., Bertheau R.C., Wong J.Y., Rao M.Y., Prasad M., Chanda D., Ponnazhagan S., Anderson K.C., Steffes C.P., Munshi N.C., De Vivo I., Beer D.G., Gryaznov S., Weaver D.W., Goyal R.K. Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin. Cancer Res. 2008, 14:4971-4980.
76. Shammas M.A., Koley H., Bertheau R.C., Neri P., Fulciniti M., Tassone P., Blotta S., Protopopov A., Mitsiades C., Batchu R.B., Anderson K.C., Chin A., Gryaznov S., Munshi N.C. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008, 22:1410-1418.
77. Marian C.O., Cho S.K., McEllin B.M., Maher E.A., Hatanpaa K.J., Madden C.J., Mickey B.E., Wright W.E., Shay J.W., Bachoo R.M. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin. Cancer Res. 2010, 16:154-163.
78. Marian C.O, Wright W.E., Shay J.W. The effects of telomerase inhibition on prostate tumor-initiating cells. Int. J. Cancer 2010, 127:321-331.
79. Molckovsky A., Siu L.L. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol. 2008, 1:20.
80. Clarke M.F, Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
81. Allan A.L., Vantyghem S.A., Tuck A.B., Chambers A.F. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2006, 26:87-98.
82. Farnie G., Clarke R.B. Breast stem cells and cancer. Ernst Schering Found. Symp. Proc. 2006, 5:141-153.
83. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
84. Brennan S.K., Wang Q., Tressler R., Harley C., Go N., Bassett E., Huff C.A., Jones R.J., Matsui W. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 2010, 5.
85. Joseph I., Tressler R., Bassett E., Harley C., Buseman C.M., Pattamatta P., Wright W.E., Shay J.W., Go N.F. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res. 2010, 70:9494-9504.
86. Castelo-Branco P., Zhang C., Lipman T., Fujitani M., Hansford L., Clarke I., Harley C.B., Tressler R., Malkin D., Walker E., Kaplan D.R., Dirks P., Tabori U. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin. Cancer Res. 2011, 17:111-121.
87. Vonderheide R.H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002, 21:674-679.
88. Vonderheide R.H., Anderson K.S., Hahn W.C., Butler M.O., Schultze J.L., Nadler L.M. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res. 2001, 7:3343-3348.
89. Vonderheide R.H., Domchek S.M., Schultze J.L., George D.J., Hoar K.M., Chen D.Y., Stephans K.F., Masutomi K., Loda M., Xia Z., Anderson K.S., Hahn W.C., Nadler L.M. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. 2004, 10:828-839.
90. Vonderheide R.H., Schultze J.L., Anderson K.S., Maecker B., Butler M.O., Xia Z., Kuroda M.J., von Bergwelt-Baildon M.S., Bedor M.M., Hoar K.M., Schnipper D.R., Brooks M.W., Letvin N.L., Stephans K.F., Wucherpfennig K.W., Hahn W.C., Nadler L.M. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001, 61:8366-8370.
91. Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., Dyrhaug M., Trachsel S., Moller M., Eriksen J.A., Gaudernack G. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006, 55:1553-1564.
92. Su Z., Dannull J., Yang B.K., Dahm P., Coleman D., Yancey D., Sichi S., Niedzwiecki D., Boczkowski D., Gilboa E., Vieweg J. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 2005, 174:3798-3807.
93. Carpenter E.L., Vonderheide R.H. Telomerase-based immunotherapy of cancer. Expert Opin. Biol. Ther. 2006, 6:1031-1039.
94. Vonderheide R.H. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov. Med. 2007, 7:103-108.
95. Danet-Desnoyers G.A., Luongo J.L., Bonnet D.A., Domchek S.M., Vonderheide R.H. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp. Hematol. 2005, 33:1275-1280.
96. Domchek S.M., Recio A., Mick R., Clark C.E., Carpenter E.L., Fox K.R., DeMichele A., Schuchter L.M., Leibowitz M.S., Wexler M.H., Vance B.A., Beatty G.L., Veloso E., Feldman M.D., Vonderheide R.H. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 2007, 67:10546-10555.
97. Minev B., Hipp J., Firat H., Schmidt J.D., Langlade-Demoyen P., Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4796-4801.
98. Nair S.K., Heiser A., Boczkowski D., Majumdar A., Naoe M., Lebkowski J.S., Vieweg J., Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 2000, 6:1011-1017.
99. Nava-Parada P., Emens L.A. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr. Opin. Mol. Ther. 2007, 9:490-497.
100. Mavroudis D., Bolonakis I., Cornet S., Myllaki G., Kanellou P., Kotsakis A., Galanis A., Nikoloudi I., Spyropoulou M., Menez J., Miconnet I., Niniraki M., Cordopatis P., Kosmatopoulos K., Georgoulias V. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 2006, 70:306-314.
101. Liu J.-P., Chen W., Schwarer A.P., Li H. Telomerase in cancer immunotherapy. Biochim. Biophys. Acta 2010, 1805:35-42.
102. Vonderheide R.H., Hahn W.C., Schultze J.L., Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-679.
103. Vonderheide R.H. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 2008, 90:173-180.
104. Arai J., Yasukawa M., Ohminami H., Kakimoto M., Hasegawa A., Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001, 97:2903-2907.
105. Hernandez J., Garcia-Pons F., Lone Y.C., Firat H., Schmidt J.D., Langlade-Demoyen P., Zanetti M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12275-12280.
106. Scardino A., Gross D.A., Alves P., Schultze J.L., Graff-Dubois S., Faure O., Tourdot S., Chouaib S., Nadler L.M., Lemonnier F.A., Vonderheide R.H., Cardoso A.A., Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol. 2002, 168:5900-5906.
107. Schroers R., Huang X.F., Hammer J., Zhang J., Chen S.Y. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002, 62:2600-2605.
108. Schroers R., Shen L., Rollins L., Rooney C.M., Slawin K., Sonderstrup G., Huang X.F., Chen S.Y. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer Res. 2003, 9:4743-4755.
109. Gross D.A., Graff-Dubois S., Opolon P., Cornet S., Alves P., Bennaceur-Griscelli A., Faure O., Guillaume P., Firat H., Chouaib S., Lemonnier F.A., Davoust J., Miconnet I., Vonderheide R.H., Kosmatopoulos K. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J. Clin. Invest. 2004, 113:425-433.
110. *0201 restricted, naturally processed CTL epitope. Cancer Immunol. Immunother. 2007, 56:1755-1763.
111. Cortez-Gonzalez X., Sidney J., Adotevi O., Sette A., Millard F., Lemonnier F., Langlade-Demoyen P., Zanetti M. Immunogenic HLA-B7-restricted peptides of hTRT. Int. Immunol. 2006, 18:1707-1718.
112. Wenandy L., Sørensen R.B., Sengeløv L., Svane I.M., thor Straten P., Andersen M.H. The immunogenicity of the hTERT540-548 peptide in cancer. Clin. Cancer Res. 2008, 14:4-7.
113. Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., Buanes T., Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br. J. Cancer 2006, 95:1474-1482.
114. Uchida N., Otsuka T., Shigematsu H., Maeda M., Sugio Y., Itoh Y., Niho Y. Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk. Res. 1999, 23:1127-1132.
115. Tahara H., Yasui W., Tahara E., Fujimoto J., Ito K., Tamai K., Nakayama J., Ishikawa F., Ide T. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 1999, 18:1561-1567.
116. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999, 59:551-557.
117. Wick M., Zubov D., Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999, 232:97-106.
118. Katz M.H., Spivack D.E., Takimoto S., Fang B., Burton D.W., Moossa A.R., Hoffman R.M., Bouvet M. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann. Surg. Oncol. 2003, 10:762-772.
119. Komata T., Kondo Y., Kanzawa T., Hirohata S., Koga S., Sumiyoshi H., Srinivasula S.M., Barna B.P., Germano I.M., Takakura M., Inoue M., Alnemri E.S., Shay J.W., Kyo S., Kondo S. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 2001, 61:5796-5802.
120. Liu J., Zou W.G., Lang M.F., Luo J., Sun L.Y., Wang X.N., Qian Q.J., Liu X.Y. Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int. J. Oncol. 2002, 21:661-666.
121. Majumdar A.S., Hughes D.E., Lichtsteiner S.P., Wang Z., Lebkowski J.S., Vasserot A.P. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther. 2001, 8:568-578.
122. Plumb J.A., Bilsland A., Kakani R., Zhao J., Glasspool R.M., Knox R.J., Evans T.R., Keith W.N. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001, 20:7797-7803.
123. Schepelmann S., Ogilvie L.M., Hedley D., Friedlos F., Martin J., Scanlon I., Chen P., Marais R., Springer C.J. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res. 2007, 67:4949-4955.
124. Zhou J.H., Tang B., Liu X.L., He D.W., Yang D.T. hTERT-targeted E. coli purine nucleoside phosphorylase gene/6-methylpurine deoxyribose therapy for pancreatic cancer. Chin. Med. J. (Engl.) 2007, 120:1348-1352.
125. Kyo S., Takakura M., Fujiwara T., Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99:1528-1538.
126. Irving J., Wang Z., Powell S., O'Sullivan C., Mok M., Murphy B., Cardoza L., Lebkowski J.S., Majumdar A.S. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 2004, 11:174-185.
127. Kawashima T., Kagawa S., Kobayashi N., Shirakiya Y., Umeoka T., Teraishi F., Taki M., Kyo S., Tanaka N., Fujiwara T. Telomerase-specific replication-selective virotherapy for human cancer. Clin. Cancer Res. 2004, 10:285-292.
128. Lanson N.A., Friedlander P.L., Schwarzenberger P., Kolls J.K., Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 2003, 63:7936-7941.
129. Wirth T., Zender L., Schulte B., Mundt B., Plentz R., Rudolph K.L., Manns M., Kubicka S., Kuhnel F. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 2003, 63:3181-3188.
130. Fujita K., Kimura M., Kondo N., Sakakibara A., Sano D., Ishiguro Y., Tsukuda M. Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma. Oncol. Rep. 2008, 20:1363-1368.
131. Nakajima O., Ichimaru D., Urata Y., Fujiwara T., Horibe T., Kohno M., Kawakami K. Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer. Oncol. Rep. 2009, 22:1039-1043.
132. Nemunaitis J., Tong A.W., Nemunaitis M., Senzer N., Phadke A.P., Bedell C., Adams N., Zhang Y.A., Maples P.B., Chen S., Pappen B., Burke J., Ichimaru D., Urata Y., Fujiwara T. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol. Ther. 2010, 18:429-434.
133. Hioki M., Kagawa S., Fujiwara T., Sakai R., Kojima T., Watanabe Y., Hashimoto Y., Uno F., Tanaka N. Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. Int. J. Cancer 2008, 122:2628-2633.
134. Liao Z., Huang C., Zhou F., Xiong J., Bao J., Zhang H., Sun W., Xie C., Zhou Y. Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. Cancer Lett. 2009, 283:20-28.
135. Zhang J.F., Wei F., Wang H.P., Li H.M., Qiu W., Ren P.K., Chen X.F., Huang Q. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J. Exp. Clin. Cancer Res. 2010, 29:52.
136. Kuroda S., Fujiwara T., Shirakawa Y., Yamasaki Y., Yano S., Uno F., Tazawa H., Hashimoto Y., Watanabe Y., Noma K., Urata Y., Kagawa S. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res. 2010, 70:9339-9348.
137. Kondo N., Tsukuda M., Kimura M., Fujita K., Sakakibara A., Takahashi H., Ishiguro Y., Toth G., Matsuda H. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Oncol. Rep. 2010, 23:355-363.
138. Takakura M., Nakamura M., Kyo S., Hashimoto M., Mori N., Ikoma T., Mizumoto Y., Fujiwara T., Urata Y., Inoue M. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther. 2010, 17:11-19.
139. Liu D., Kojima T., Ouchi M., Kuroda S., Watanabe Y., Hashimoto Y., Onimatsu H., Urata Y., Fujiwara T. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol. Cancer Ther. 2009, 8:980-987.